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ABSTRAK
Latar belakang: acoustic radiation force impulse (ARFI) merupakan metode non invasif baru untuk 
penilaian derajat fibrosis hati. Dengan adanya integrasi ultrasonografi mode B, ARFI dapat digunakan untuk 
menilai kondisi jaringan hati. Meskipun demikian, kemampuan diagnostik ARFI saat ini masih terus dievaluasi. 
Terlebih lagi, belum tersedia data mengenai penggunaan ARFI pada populasi kami. Penelitian ini bertujuan 
mengevaluasi kemampuan diagnostik ARFI sebagai alternatif modalitas penilaian derajat fibrosis secara non 
invasif pada pasien hepatitis B dan hepatitis C kronik pada populasi kami. Metode: dilakukan penelitian potong 
lintang untuk membandingkan gambaran ARFI dan elastografi transien pada pasien yang diperiksakan biopsi 
hepar di Rumah Sakit Cipto Mangunkusumo. Derajat fibrosis menggunakan sistem skor METAVIR sebagai 
acuan baku. Sebanyak 43 pasien diikutsertakan dalam penelitian ini. Nilai cut-off ditentukan berdasarkan kurva 
receiver-operating characteristic (ROC). Hasil: derajat kekakuan hati melalui pemeriksaan ARFI maupun 
transien elastografi (TE) berkorelasi sedang dengan skor METAVIR dengan skor masing-masing 0,581 dan 
0,613 (p<0,01). Akurasi diagnostik ARFI untuk memprediksi fibrosis signifikan (F≥2) memiliki area under 
receiver operating characteristic curve (AUROC) 0,773 (IK 95% 0,616-0,930) dan bahkan jauh lebih baik untuk 
sirosis (fibrosis F4), ditunjukkan dengan AUROC 0,856 (IK 95% 0,736–0,975). Elastografi transien memiliki 
kemampuan diagnostik lebih baik untuk fibrosis signifikan dengan AUROC 0,761 (IK 95% 0,601–0,920) dan 
paling baik untuk prediksi sirosis, dengan AUROC 0,845 (IK 95% 0,722–0,968). Kesimpulan: ARFI merupakan 
prosedur evaluasi kondisi jaringan hati yang lebih praktis, dengan akurasi kemampuan diagnostik yang tidak 
berbeda secara signifikan dengan elastografi transien untuk menentukan derajat fibrosis hati.
Kata kunci: acoustic radiation force impulse (ARFI), fibrosis, elastografi transien, biopsi hepar.
ABSTRACT
Background: acoustic radiation force impulse (ARFI) is a new proposed noninvasive method for liver fibrosis 
staging. Integrated with B-mode ultrasonography, ARFI can be used to assess liver tissue condition. However its 
diagnostic accuracy is still being continuously evaluated. Also, there is lack of data regarding the utilization of 
ARFI in our population. This study aimed to evaluate the diagnostic value of ARFI as an alternative noninvasive 
modality for fibrosis staging in chronic hepatitis B and hepatitis C patients in our population. Methods: we 
conducted cross-sectional comparison of ARFI imaging and transient elastography on patients who underwent 
liver biopsy at Cipto Mangunkusumo Hospital. Fibrosis staging using METAVIR scoring system presented as 
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standard reference. A total of 43 patients underwent liver biopsy was evaluated by ARFI imaging and transient 
elastography. Cut-off values were determined using receiver-operating characteristic (ROC). Results: both liver 
stiffness determined by ARFI and transient elastography (TE) were moderately correlated with METAVIR score 
with value of 0.581 and 0.613, respectively (both P<0.01). Diagnostic accuracy of ARFI predicted significant 
fibrosis (F≥2) with area under receiver operating characteristic curve (AUROC) of 0.773 (95% CI 0.616-0.930) 
and even better for cirrhosis (F4 fibrosis), expressed as AUROC of 0.856 (95% CI 0.736–0.975). Transient 
elastography was better for significant fibrosis with AUROC of 0.761 (95% CI 0.601–0.920) and was best for 
prediction of cirrhosis, expressed as AUROC of 0.845 (95% CI 0.722–0.968). Conclusion: ARFI is provided 
with more convenient evaluation of liver tissue condition, and its diagnostic accuracy is not significantly different 
from TE for staging liver fibrosis.
Keywords: acoustic radiation force impulse (ARFI), fibrosis, transient elastography, liver biopsy.
INTRODUCTION
Hepatic fibrogenesis may gradually result in 
cirrhosis due to the accumulation of extracellular 
matrix components as a response to liver injury. 
Thus, therapeutic decisions in chronic liver 
disease, regardless of the cause, should first and 
foremost be guided by an accurate quantification 
for hepatic fibrosis.1 The examination can be 
done with invasive or non-invasive methods. 
Liver biopsy remain the gold standard in 
assessing the degree of liver fibrosis, which plays 
an important role in determining therapy for 
patients and monitoring the success of therapy.2-4 
However, biopsy is an invasive procedure which 
has weaknesses, thus non-invasive technology 
with excellent sensitivity and specificity was 
developed to assess the degree of liver fibrosis.2 
Their most important advantages are the absence 
of contraindications and dangerous complications 
for the patients, and their reproducibility.1
Current transient elastography (TE) enjoys 
great popularity. Result from previous study 
showed that TE had a good sensitivity and 
specificity, so it can be used to assess the 
degree of liver fibrosis, to monitor the success 
of therapy, and to predict mortality and severe 
outcome in patients with chronic liver disease.5 
Some of the non-invasive examination methods 
were continued to be developed, such as acoustic 
radiation force impulse (ARFI).6
Some studies comparing ARFI and TE 
showed various results because the baseline of 
the patients varied from one to another study. 
However, a meta-analysis of thirteen studies 
found that ARFI has similar accuracy as TE, but 
also has other advantages in other terms. ARFI 
is integrated into the ultrasound machine, so that 
the patient does not require two examinations, 
namely ultrasound and fibrosis measurements.7 
The failure rate as invalid measurement of ARFI 
has also been reported to be significantly lower 
than TE (0 vs 6.5%).8,9
However, quality criteria for ARFI to provide 
consistent and reproducible results is often less 
clear.8 Unlike TE, the use of ultasound image 
to choose the positioning of region of interest 
in both planes will be less sensitive to the 
presence of ascites and to obesity. Moreover, 
steatosis, acute inflammation, and food intake 
may interfere with hepatic stiffness.10,11 There is 
also no provision location and depth led to the 
emergence of various results on ARFI compared 
to TE.6 To the best of our knowledge, there is lack 
of study assessing the utilization of ARFI in our 
population. Also, recent studies were focused 
on hepatitis C patients, meanwhile in practice 
hepatitis B patients are actually in greater 
proportion. Therefore, we conduct this study to 
gain more data in order to evaluate the diagnostic 
value of ARFI as an alternative noninvasive 
modality for fibrosis staging in chronic hepatitis 
B and hepatitis C patients in our population.
METHODS
This study was a diagnostic study with cross-
sectional design. All subjects underwent liver 
biopsy, transient elastography (TE) and acoustic 
radiation force impulse (ARFI). This study was 
conducted from August 2013 to February 2014 
in Cipto Mangunkusumo Hospital Jakarta. The 
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study population was patients aged more than 
18 years old with chronic hepatitis who wanted 
to start treatment. Patients with non alcoholic 
fatty liver disease (NAFLD) or liver malignancy 
were excluded. Those who agreed to be a subject 
gave informed consent and signed it. Ethical 
clearance was issued by the Ethics Committee of 
the Faculty of Medicine, Universitas Indonesia/ 
Cipto Mangunkusumo Hospital, with approval 
number 144/H2.F1/ETIK/2014.
Liver Histology
Liver biopsy was performed under local 
anesthesia. Formalin was used for the specimens 
fixation, and then the specimens were embedded 
in paraffin blocks. Staining after cutting the 
specimens was done by the pathologist with 
haematoxylin and eosin. Fibrosis was assessed 
using masson trichrome staining, measured 
based on METAVIR scoring system (F0, no 
fibrosis; F1, portal fibrosis without septa; F2, 
portal fibrosis and few septa; F3, numerous septa 
without cirrhosis; F4, cirrhosis). Significant 
fibrosis was defined as stage F2 or more.
ARFI Imaging
Acoustic radiation force impulse (ARFI) 
is a technology developed to measure tissue 
elasticity, using a shear wave velocity. ARFI 
can be used on a variety of tissue regions, 
such as the thyroid gland, mammary gland and 
abdominal organs such as the liver and spleen. 
ARFI has two methods to assess the elasticity of 
tissues, namely liver relative tissue stiffness and 
quantitative liver stiffness. Both are combined 
to assess tissue elasticity. ARFI is a tool that 
resembles the ultrasound, with probe that capable 
of generating vibrations. Relative liver stiffness 
is measured by attaching the probe to the desired 
region. The probe will then emit pulsations to the 
middle of the region with a frequency of 2.67 
MHz and then the pulse wave is received back 
and be compared. In this examination, the stiff 
area is seen as a darker-colored area.
Quantitative liver stiffness was measured 
using a pulse emitted by a probe attached to the 
target region. The pulse would cause vibration 
1–10 m/s at all tissue region. This vibration is 
called shear wave. This vibration was amplified 
by the coefficient that significantly higher than 
the longitudinal ultrasound waves. Shear wave 
velocity was measured by looking and analyzing 
the waves that cameback from various locations. 
Shear wave correlated with tissue elasticity, 
in which the faster the shear wave, the less 
elastic the tissue was. ARFI procedure took 
approximately 5 minutes for each examination.
Transient Elastography
Transient elastography (TE) is a non-invasive 
method to assess the degree of liver stiffness. The 
probe in TE works to emit amplitude vibration at 
medium and low frequency (50 Hz), generating 
an elastic shear wave that moves through the 
tissue under the probe. Shear wave velocity is 
followed and measured. The more rigid the liver 
tissue, the faster the shear wave will move.
Examination using TE only took a short time 
and could easily be tolerated by patients. The 
inspection carried out in the right region of the 
liver through the intercostal space. Patient lied in 
the dorsal decubitus position with the right arm to 
be in maximum abduction. The examination was 
performed 10 times, with the median value of 
the 10 times examination describe the elasticity 
of the liver.
Statistical Analysis
Data of patients who underwent liver 
biopsy evaluated by ARFI imaging and 
transient elastography were analysed. Baseline 
characteristics were reported descriptively, 
with mean and standar deviation for numeric 
data. Correlation between ARFI and METAVIF 
fibrosis stage as well as ARFI with TE were 
evaluated with Spearman correlation test. Cut-
off values for ARFI or TE were determined 
using receiver-operating characteristic (ROC), 
respectively. Fibrosis staging using METAVIR 
scoring system presented as standard reference 
for ARFI and TE. All statistical analysis were 
executed with SPSS 20.0.
RESULTS
A total of 50 patients with chronic liver 
disease underwent liver biopsy. Among them, 5 
patients were excluded due to non-hepatitis B and 
C etiology and 2 others due to non-representative 
biopsy for staging. All patients routinely 
attended hepatobiliary procedure room of Cipto 
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Mangunkusumo Hospital and were randomly 
selected to participate in the study. Forty-three 
patients underwent ARFI elastography, transient 
elastography, and successful liver biopsy (Figure 
1). Characteristics of patients are shown in Table 
1.
than 88% patients had significant fibrosis, 
whereas none of our subjects was in F0 stage.
Relationship Between ARFI Liver Elasticity 
and METAVIR Score
Moderate correlation of increasing liver 
stiffness with severity of fibrosis was found. 
The Spearman’s correlation coefficient between 
ARFI liver elasticity and METAVIR score was 
significant with value of 0.608, p<0.01 (Figure 
2).
Patients with liver biopsy
n = 50
Excluded from the study
(autoimmune, parenchymal
jaundice)
n = 5 Liver biopsy
not representitve for staging
n = 2
Patients underwent fibroscan and ARFI
n = 43
Figure 1. Diagram of chronic liver disease patients 
underwent liver biopsy at Cipto Mangunkusumo hospital 
during 12-month study period
Table 1. Patients characteristics
Characteristics Value
Demography (n=43)
 - Male, n (%) 31 (72.1)
 - Age, mean (SD), (years) 47.37 (12.67)
Laboratory data, mean (SD)
 - AST (IU/L) 71.12 (56.71)
 - ALT (IU/L) 100.04 (78.12)
 - Bilirubin (mg/dL) 0.83 (0.35)
 - Albumin (g/dL) 4.39 (0.56)
 - Platelet count (x 103/μL) 164.84 (63.23)
Chronic liver diseases, n (%)
 - Chronic hepatitis B 14 (32.6)
 - Chronic hepatitis C 29 (67.4)
Fibrosis staging (METAVIR), n (%)
 - F0 0 (0)
 - F1 5 (11.6)
 - F2 11 (25.6)
 - F3 12 (27.9)
 - F4 15 (34.9)
Our study subjetcs were predominantly 
male with the ratio of 2,6:1 compared to female. 
Chronic hepatitis C was found in greater 
proportion (67%) than hepatitis B (33%). More 
r=0.608
p<0.01
Figure 2. Correlation of ARFI and METAVIR score
We use ROC curve method to determine 
the cut-off for each degree of fibrosis (Figure 
3). ARFI was able to predict significant fibrosis 
(F2 or more), with validity of 77.3% (95% CI 
AUROC = 0.616 – 0.930). The optimal median 
cutoff point between F1 and F2 was 1.32. At 
this value, ARFI elastography had a sensitivity 
of 68% and a specificity of 80%. ARFI showed 
better performance in predicting F3 or F4 fibrosis 
(AUROC = 78.5%, 95% CI = 0.639 – 0.932). 
The optimal median cut-off between F3 and F4 
fibrosis was same at 1.32, with sensitivity and 
specificity of 82% and 73%, respectively.
ARFI predicted best for cirrhosis or non 
cirrhosis (F4 or <F4) (AUROC = 85.6%, 95% 
CI = 0.736-0.975). The optimal median cut-off 
was 1.71, with sensitivity and specificity of 80% 
and 85%, respectively. The most selective cutoff 
values of ARFI with corresponding sensitivity, 
specificity, PPV and NPV were shown in Table 2.
By etiology, patients with chronic hepatitis 
B tends to have lower cut-off values of ARFI in 
determining fibrosis stages compared to those 
Rino A. Gani                                                                                                                            Acta Med Indones-Indones J Intern Med
132
> F2 fibrosis > F3 fibrosis
F4 fibrosis
Figure 3. ROC curve for ARFI in predicting fibrosis stages
Table 2. Most selective cut-off values of ARFI and TE in determining fibrosis stages
All patients  
(n = 43) Cut-off for F≥2 Se (%) Sp (%) PPV (%) NPV (%)
ARFI 1.32 (m/s) 68 80 96 25
TE 8.55 (kPa) 66 80 96 24
Cut-off for F≥3
ARFI 1.32 (m/s) 82 73 85 67
TE 10.3 (kPa) 71 87 91 62
Cut-off for F4
ARFI 1.71 (m/s) 80 85 75 89
TE 12.8 (kPa) 86 82 75 92
with chronic hepatitis C. For chronic hepatitis 
B, the optimal median cut-off points between F1 
and F2, F2 and F3, F3 and F4 were 0.97 (AUC 
84.6%, 95% CI 0.650-1.042), 1.23, and 1.64 
(AUC 92.5%, 95% CI 0.774-1.076), whereas 
in chronic hepatitis C were 1.32 (AUC 80.2%, 
95% CI 0.633-0.972), 1.48, and 1.79 (AUC 
80.2%, 95% CI 0.628-0.976), respectively. 
The most selective cut-off values of ARFI with 
corresponding sensitivity, specificity, PPV and 
NPV by etiology were shown in Table 3.
Relationship Between Transient Elastography 
and METAVIR Score
The Spearman’s correlation coefficient 
between transient elastography liver stiffness 
and METAVIR score was significant with value 
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of 0.705 (95% CI 0.645-0.766, p<0.01).
We use ROC curve method to determine the 
cut-offs for each degree of fibrosis (Figure 4).  TE 
predicted significant fibrosis (F2 or more), with 
validity of 76.1% (95% CI AUC = 0.601–0.920). 
The optimal cut-off point between F1 and F2 
was 8.55. At this value, TE had a sensitivity of 
66% and a specificity of 80%. TE showed better 
performance in predicting F3 or F4 fibrosis (AUC 
= 81.1%, 95% CI = 0.683–0.938). The optimal 
cut-off between F3 and F4 fibrosis was 10.3, 
with sensitivity and specificity of 71% and 87%, 
respectively. TE predicted best cirrhosis or non 
cirrhosis (F4 or <F4) (AUC = 84.5%, 95% CI 
= 0.722-0.968). The optimal cut-off was 12.8, 
with sensitivity and specificity of 86% and 82%, 
respectively. The most selective cut-off values 
of TE with corresponding sensitivity, specificity, 
PPV and NPV were shown in Table 2.
Applicability and Correlation of ARFI and 
Transient Elastography in All Patients
Both ARFI and transient elastography had 
been performed successfully in all patients. We 
Table 3. Most selective cut-off values of ARFI in determining fibrosis stages by etiology
Etiology Cut-off for F≥2 Se (%) Sp (%) PPV (%) NPV (%)
Hepatitis B 0.97 (m/s) 85% 100% 100% 33%
Hepatitis C 1.32 (m/s) 79% 75% 95% 38%
Cut-off for F≥3
Hepatitis B 1.23 (m/s) 67% 60% 75% 50%
Hepatitis C 1.48 (m/s) 78% 80% 67% 78%
Cut-off for F4
Hepatitis B 1.64 (m/s) 100% 90% 80% 100%
Hepatitis C 1.79 (m/s) 72% 82% 73% 82%
> F2 fibrosis > F3 fibrosis
F4 fibrosis
Figure 4. ROC curve for TE in predicting fibrosis stages
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found significant correlation between ARFI and 
transient elastography, with r = 0.562, 95% CI 
= 0.472-0.636, p<0.01 (Figure 5).
DISCUSSION
Over the last 10-15 years, major efforts have 
been made by various groups all over the world to 
establish reliable and reproducible noninvasive 
markers of liver fibrosis to substitute liver 
biopsy. This study showed that the estimation 
of shear wave velocity using ARFI could be 
used as a diagnostic tool for significant fibrosis 
and cirrhosis, with accuracy as high as TE. We 
found moderate correlation between ARFI and 
FibroScan with r=0.562 (p <0.01), consistent 
with other research by Crespo et al.12 in which 
ARFI correlated even stronger and more 
significant with FibroScan in chronic liver 
diseases non transplant patients with r=0.826 
(p<0.001).
In regards to diagnostic accuracy of ARFI 
technique for each liver fibrosis, we found that 
ARFI elastography could predict different grades 
of liver fibrosis with reasonable sensitivity 
and specificity. The highest AUC found in 
later fibrosis, with 82% sensitivity and 73% 
specivicity for F3, and 80% and 85% for F4, 
respectively. Our findings agree with previous 
studies, a meta-analysis of thirteen studies by 
Bota et al.7, which showed that ARFI was highly 
accurate for the diagnosis of cirrhosis compared 
to earlier fibrosis, with 87% sensitivity and 87% 
specificity, not significantly different compared 
to 89% and 87% for TE.
We obtained larger AUROC for patients with 
hepatitis B than hepatitis C, particulary in F2 
(84.6% vs 80.2%) or F4 (92.5 vs 80.2%) fibrosis 
stage. For hepatitis C infection itself, Rizzo et 
al.9 showed quite similar finding for F2 (cut-off 
1.3, sensitivity 81%, specificity 70%), but larger 
cut-off (1.7 and 2.0), thus larger sensitivity (91% 
and 83%) and specificity (86% and 86%) for 
F3 and F4. Tai et al.13 found that patients with 
hepatitis C in his study had a higher AUROC 
than patients with hepatitis B (0.824 versus 
0.707) in predicting liver cirrhosis. Friedrich, et 
al.6 also stated that liver fibrosis in hepatitis C 
are more homogenously distributed, compared 
to macronodular and episodic acute exacerbation 
form with more severe confluent necrosis of 
hepatitis B.
Elhosary, et al.14 found that ARFI elastography 
was properly correlated with biochemical markers 
for hepatitis as it was directly correlated to AST, 
ALT, and INR, while it was inversely correlated 
to albumin, prothrombin concentration, and 
platelets. ARFI measurement is generally 
recommended after the stabilization of ALT or 
resolve of the inflammatory condition. Therefore, 
our result revealed in hepatitis B patients which 
was higher could be influenced by the episodic 
alteration of ALT and AST.13,15
The inclusion of ARFI in an ultrasound 
device could facilitate its incorporation into 
routine clinical practice. This ultrasound 
guidance is particularly helpful for ensuring that 
the region of interest is placed in such a way 
that it avoids nearby vessels and ribs, giving 
significant advantage. ARFI may also expand its 
utilization when TE is difficult to be performed, 
especially in patients with morbid obesity or 
marked ascites. Moreover, ultrasound permits 
the evaluation of portal diameter, splenomegaly, 
and liver surface, which has recently been shown 
to be highly accurate in the diagnosis of early 
cirrhosis.12
To the best of our knowledge, this study is the 
first to explore the role of ARFI as a non-invasive 
diagnostic technique for liver fibrosis among our 
population. It is important to acknowledge that 
the analysis was carried out in a relatively small 
number of patients, and it would be interesting to 
r=0.562
p<0.01
Figure 5. Correlation of ARFI and FibroScan
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see if these results also hold true in larger groups 
of patients. In spite of that, all enrolled patients 
came from all over the country, thus, we think our 
patient’s sample represented our population well.
Our subjects had chronic liver disease either 
due to hepatitis B or hepatitis C virus infection. 
Although our findings would require further 
confirmation in single-etiology studies, perhaps 
the current study are representative of what 
is typically seen in routine clinical practice. 
However, it should be kept in mind that more 
heterogenous nature could be encountered in 
daily clinical work, especially for alcoholic, non 
alcoholic fatty liver disease, and autoimmune 
hepatitis. Thus, future studies regarding the use 
of ARFI evaluation per fibrosis level for those 
etiologies in our population will complete our 
current data.
CONCLUSION
In summary, we believe that there is 
sufficient evidence that ARFI should be taken 
into consideration as a non-invasive method 
for evaluation of liver fibrosis in patients with 
chronic liver disease, as ARFI is provided with 
more convenient evaluation of liver tissue 
condition and its diagnostic accuracy is similar 
from TE for staging liver fibrosis.
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